AR and prostate carcinoma: Selective inhibition on androgen receptor (AR)-negative prostate cancer cell growth; induction of apoptosis with associated increased expressions of proapoptotic proteins: death receptor-5, Bim, Puma and downregulation of XIAP and survivin expressions.